2022: Successful transformation into a commercial stage company - Form 6-K

2022: Successful transformation into a commercial stage company


"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for... | February 23, 2023

Related Keywords

China ,Sweden ,Japan ,United States ,Stockholm ,United Kingdom ,Switzerland ,Japanese ,Chinese ,American ,Marie Galay ,Kidney International ,Viatris Pharmaceuticals Japan ,Viatris Pharmaceuticals Japan Inc ,European Commission ,European Commission For Kinpeygo ,American Society Of Nephrology ,National Medical Products Administration ,European Union Member States ,American Society ,Kidney Week ,Everest Medicines ,New Drug Application ,Priority Review ,China Everest Medicine ,Events After ,Reporting Period ,Conditional Marketing Authorization ,European Economic Area ,Presentation February ,Nasdaq Stockholm ,American Depositary Shares ,Nasdaq Global Select Market ,Calliditas Therapeutics Ab Publ Stock Exchange ,News ,Information ,Press Release ,Uccessful ,Transformation ,Into ,Commercial ,Stage ,Gas ,Fantastic ,Ear ,Or ,Calliditas ,Us ,The ,Aunched ,N ,He ,First ,Approved ,Rug Caltx Se0010441584 ,